Feedback EMEA / Industry Discussion

Similar documents
Analytical Methods and Sampling in the New Manufacturing Paradigm a Regulatory Perspective

Q8 and Q8 annex An industry Perspective

QbD/PAT Implementation: The Road to RTR From Science to Compliance

CMC Topics and PMDA s activities Yoshihiro Matsuda, Ph.D.

Claus Mortensen, Medicines Inspector. Danish Medicines Agency. Member of the EMEA PAT team

Value Paper. Are you PAT and QbD Ready? Get up to speed

Implementation of ICH Q8 and QbD An FDA Perspective

Quality by Design and OINDP. Today s Presentation

EDQM Conference. Quality of Medicines in a Globalised World: Dreams and Reality

PMDA perspective on Quality by Design for pharmaceutical products

VisioNIR. High Speed NIR Spectrometer for 100% Process Inspection

Association. Innovation in Medicines PDA: A Global. and Manufacturing. David Tainsh, GSK Keith Pugh, MHRA

ICH Q8, 9 & 10 and the Impact on the QP

Quality by Design. Innovate Design Development Create value. Correct definition of QbD and its relation to product and process development

ConsiGma TM, a platform for continuous processing

QUALITY: BRACKETING AND MATRIXING DESIGNS FOR STABILITY TESTING OF NEW VETERINARY DRUG SUBSTANCES AND MEDICINAL PRODUCTS

STRATEGIES FOR SUCCESSFUL SCALE-UP USING QUALITY BY DESIGN

ICH Q8 / ICH Q11 Training Course

Future of Pharmaceutical Quality and the Path to Get There

Update on Lessons Learned from the EMA-FDA QbD Pilot

How Process Models can Facilitate Quality Risk Management for Emerging Technologies

Progress in FDA s Drug Product Quality Initiative. Janet Woodcock, M.D. November 13, 2003

The Process Analytical Technology Initiative: PAT and the Pharmacopeias

Challenges of Implementation of ICH Q 8

Implementing Quality Systems

Process Analytical Technology (PAT): A Real Time Quality Assurance

Innovative Approaches to Pharmaceutical Development and Manufacturing Seminar Series

Spectrum 400. FT-IR and FT-NIR Spectrometer. There is only one answer.

Terrence Tougas. Dennis Sandell

EDQM COUNCIL OF EUROPE CONFERENCE CERTIFICATION PROCEDURE : 20 YEARS OF EXPERIENCE March EDQM, Strasbourg, France ABSTRACTS

PROCESS ANALYTICAL TECHNOLOGY (PAT) - AS A CULTURE OF INNOVATION

International Journal of Pharma and Bio Sciences PROCESS ANALYTICAL TECHNOLOGY IMPLEMENTATION- PROGRESSION FOR A PHARMACEUTICAL INDUSTRY ABSTRACT

EU GMP Evolution or Revolution Scope and drivers for EU GMP changes. August Gordon Farquharson

Half Day Course 2 Chemometrics

Technology to meet the needs of patients around the world

Impact of ICH Q9 and the application of Risk Management

Symposium on Continuous Manufacturing of Pharmaceuticals Notes

CENTRE FOR PROCESS ANALYTICS AND CONTROL TECHNOLOGY.

From API to Formulated Product

Importance of ICH Guidance in Fulfilling Process Validation Requirements

Building Toward a Modern Pharmaceutical Manufacturing Sector: Encouraging Development and Adoption of Emerging Technology

Technology Transfer Plays an Increasingly Important Role in Pharmaceutical Quality Systems

the SPD company Dr Clive Simon, Principal, The SPD Company.

PTG NIR. Powder Analysis System

The GEA Pharma Solids Center. Improving your products, optimizing your processes, making science work

How CDER is Encouraging Adoption of Emerging Technologies in Pharmaceutical Industry

Analytical Development Labs

Introduction. Methods: Spherical Granulation. Shawn Engels, Vector Corporation

Progressive Licensing and the Modernization of the Canadian Regulatory Framework

Pharmaceutical Process Development

ICH Q12 (Pharmaceutical Product Lifecycle Management): PMDA Perspective

VideometerLab 3 Multi-Spectral Imaging


Timescales for Change A Look at Innovation in the Pharmaceutical Industry

Section heading. Strapline sub-heading

Building quality into HTA and Coverage Decision- Making Processes: What are the features of good practice in HTA?

peace of mind For from development to commercial supply

TECH TRANSFER University Joins Industry. Maite Aguado Pharmaceutical Technology PL Synthon Hispania

Pharmaceutical Manufacturing and Engineering Catalog Excerpt

QbD Application in Japan: PMDA Perspective

Pharmaceutical Manufacturing Technology Centre (PMTC) Detailed Description of Needs Document April 2012

Granulation & Tableting

The Changing Face of Product and Process Development in the QbD Era. James Kraunsoe AstraZeneca Product Development UK/US

Office of Pharmaceutical Quality Key Quality Initiatives

More Detail. Faster. Easier. The results will inspire you. Spotlight 400

Quality assurance in the supply chain for pharmaceuticals from the WHO perspective

Global GMP Harmonisation A Japanese Perspective

CDRH PMA Critical to Quality (CtQ) Pilot

Quality by Design, Clinical Relevance & Lifecycle Considerations

Agilent 8700 LDIR Chemical Imaging System. Bringing Clarity and Unprecedented Speed to Chemical Imaging.

Application of Visible-Residue Limit for Cleaning Validation Richard J. Forsyth and Vincent Van Nostrand By Richard J. Forsyth,Vincent Van Nostrand

Claudio Pincus, President, The Quantic Group R. Owen Richards, President, Quantic Regulatory Services Daniel Pincus, Consultant, The Quantic Group

Annual Benefit-Risk Workshop

D1.10 SECOND ETHICAL REPORT

Convergence and Differentiation within the Framework of European Scientific and Technical Cooperation on HTA

Workshop 239 HANDS ON: CONTINUOUS OSD PHARMA PROCESSING A forward looking approach for the production of oral solid dosage forms.

Workshop 240 GRANULATION & TABLETING PROCESS Innovative process and tools to achieve the perfect OSD product April 2018

OSIsoft. Users Conference 2013

Workshop: GRANULATION & TABLETING New requirements for an established technology - robustness, efficiency and quality.

Janie Dubois, Jean-Claude Wolff, John K. Warrack, Joseph Schoppelrei, and E. Neil Lewis

OMCL Network of the Council of Europe GENERAL DOCUMENT

CENTER FOR DEVICES AND RADIOLOGICAL HEALTH. Notice to Industry Letters

Foreign Particulate Matter testing using the Morphologi G3

Process Validation to Improve Food Safety Meat and Poultry. James S Dickson Inter-Departmental Program in Microbiology Department of Animal Science

LIGHTHOUSE. The Science of Pharmaceutical Manufacturing

Connecting People, Science and Regulation

Innovative technologies for powder processing

Continuous Manufacturing, Emerging Technology and the Office of Pharmaceutical Quality

Chemical Imaging. Whiskbroom Imaging. Staring Imaging. Pushbroom Imaging. Whiskbroom. Staring. Pushbroom

Services of a Neutral Beam Specialist for the Neutral Beam Section of the Heating & Current Drive Division of ITER. Technical Specifications

European Commission Health and Consumers Directorate General, Brussels

Manufacture of medicinal products in Italy: challenges for the Italian Medicines Agency

Installation and User Guide. FlexIR TM NIR Fiber Optic Accessory

A Comparison between Validating Laboratory and Process Near-Infrared Spectrophotometers

The Effect of Coating Process Conditions and Coating Formula Type on the Quantity and Location of Water in Film Coated Tablets

Raman Imaging: Unlocking Solid Dosage Form Evaluation. Robert Heintz, Ph.D. Senior Applications Specialist

KEY HIGHLIGHTS WORKSHOP 2019

Embracing Quality by Design. Applying QbD concepts can help CMOs create value

nuclear science and technology

The New Techpap NIR spectroscopy for Recycled Paper Bales Inspection

Transcription:

Feedback EMEA / Industry Discussion Eli Lilly & Co Ltd Case Study: Use of In-Line Near-Infrared Spectroscopy to Monitor Segregation of a Pharmaceutical Powder Blend in a Tablet Press Martin Diller PhD, Federal Institute for Drugs & Medical Devices (BfArM), Germany John Kerridge PhD, Eli Lilly & Co Ltd, United Kingdom 29/09/2009 EMEA/Efpia QbD Application Workshop - London

Case Study Summary Real time powder uniformity monitoring during compression Non-contact NIR probe NIR probe positioned in Fill-o-matic Feeder Frame, prior to tablet compression. ~ 10 15 mm from tablet die. Technique allows for :- rapid & non-destructive content uniformity assessment segregation determination of the blended materials, both API and excipients, going directly into the final pharmaceutical solid dosage form, i.e. tablet. 29/09/2009 EMEA/Efpia QbD Application Workshop - London 2

Case Study Summary NIR System - Rapid data acquisition times (<35 milliseconds per spectrum) Shown to provide an alternate strategy for demonstrating adequacy of mixing of powder blends Excellent potential to monitor a larger fraction of the entire blended sample preparation Improved statistical description of variation within an entire production batch. Improvement on PQRI Draft Guidance recommendation of using stratified sampling of both the blend and dosage units at specifically targeted locations 29/09/2009 EMEA/Efpia QbD Application Workshop - London 3

Case Study Summary % Drug Content Layered in chute Layered powder fractions of differing concentration in tablet hopper 5.5% 4.5% 4.0% 4.5% 7 6 5 NIR Estimate HPLC Measurement Accurate product monitoring in real-time throughout the batch Concentration, % 4 3 2 1 NIR Data 0 50 100 150 200 Elasped Time, minutes 29/09/2009 EMEA/Efpia QbD Application Workshop - London 4

Case Study Summary Conclusion In-line NIR method provides for an additional tool in the QbD/PAT tool box Can be used to assess and identify critical sources of process and product variability Eg correlating properties such as particle size, shape, density, surface texture, cohesiveness, etc. to powder flow and uniformity Enables production of a more consistent product that meets predefined critical quality attributes. With development may provide an opportunity for alternative product testing strategies 29/09/2009 EMEA/Efpia QbD Application Workshop - London 5

Main Topics Discussed Technical questions Introduction of novel technologies Data required in submissions When does novel become platform Development improving Process / Product Knowledge Traditional versus monitoring sampling techniques Data presentation for assessment (quantity/section) Bridging studies between traditional and novel techniques Pure process knowledge information does it need to be presented for review 29/09/2009 EMEA/Efpia QbD Application Workshop - London 6

Main Topics Discussed Design space / Control strategy Data for process understanding / development purposes Potential use as real time release test Regulatory Framework Current regulatory framework changes needed to enable implementation Provision of timely advice on new CMC approaches 29/09/2009 EMEA/Efpia QbD Application Workshop - London 7

Common Understanding NIR spectroscopy is a potential and suitable tool for controlling process and product quality NIR could replace existing IPC NIR could add to existing IPC to povide enhanced information on manufacturing process NIR measurement provides increased knowledge of process variability Increased sampling frequency (continuous verification) Does this provide a basis for changing conventional thinking and decision making? EMEA NIR guidance is currently under review 29/09/2009 EMEA/Efpia QbD Application Workshop - London 8

Common Understanding Concept development Potential for technique to replace end-product-testing (real time release testing) Thorough risk assessment and evaluation needed Understand key parameters Eg impact of machine type, influence of excipients Dossier submissions for new technologies Explain concepts, science and summarise key data Supporting information eg spectra would be reviewed at inspection A PAT defined control strategy would need to be fully integrated into a Quality Management System Eg. Atypical results, Out of specification process Strategy may be specific to technology / technique 29/09/2009 EMEA/Efpia QbD Application Workshop - London 9

Areas for further work Defined structures for training and advice are necessary (industry and regulators) e.g. workshops, presentation s on new PAT approaches Take opportunities for using EMEA PAT team and Scientific Advice procedures accurate definitions, interactive dialogue, accepted agreements Regulatory guidance should be adjusted appropriately e.g. Variations, NIR, RTR testing, process validation 29/09/2009 EMEA/Efpia QbD Application Workshop - London 10

Areas for further work Changing the perspective different approaches may match or improve on traditional methods through analysis of different information Eg Uniformity of dose could be replaced by continuous evaluation of powder blend uniformity and tablet weight New technology principles need to be explained Statistical approaches Ensure approaches (data filtering) are scientifically valid Eg use of standard diagnostic techniques How to demonstrate that the data analysis has looked at the positive and negative influences on the data set? Where best to describe data analysis models? Consider industry / regulator training programmes on specific techniques - Eg Multivariate data analysis 29/09/2009 EMEA/Efpia QbD Application Workshop - London 11

Conclusion In-line estimation of API concentration of a flowing powder in a tablet press has been demonstrated using a NIR probe and a good chemometric model. Further development may allow traditional control and testing strategies to be changed continuous verification Successful development and implementation of such techniques will require discussion and adaptation of regulatory frameworks & submission content Regulators and industry share common views on what can be achieved further discussion to allow successful implementation will continue 29/09/2009 EMEA/Efpia QbD Application Workshop - London 12